E-learning 4 Things to know about CKD and SGLT2i
Accredited e-LearningOnline-CME - This course consists of 4 parts.
This educational program consists of four presentations on CKD and SGLT2 inhibitors.
This course consists of the following:
- What is the evidence of SGLT2i in CKD? - Hiddo L. Heerspink, PhD – Groningen, The Netherlands
- When and how to initiate SGLT2i in CKD - David Wheeler, MD – London, UK
- A call to action: optimizing treatment in CKD - Meg Jardine, MD, PhD – Sydney, Australia
- Primary care role in CKD - Richard Hobbs, MD – Oxford, UK
How to obtain your CME certificate
- Watch the four lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate (if your score >70%)
After watching these three videos, the learner should be able to:
- Discuss results of kidney outcomes trials with SGLT2 inhibitors
- Recall what to take into account when initiating SGLT2 inhibitors
- Illustrate the situation of current prescription of SGLT2 inhibitors by nephrologists
- Describe the role of primary care in CKD
- Hiddo L. Heerspink, PhD – Groningen, The Netherlands
- David Wheeler, MD – London, UK
- Meg Jardine, MD, PhD – Sydney, Australia
- Richard Hobbs, MD – Oxford, UK
This educational activity is designed for all healthcare professionals with an interest in management of patients with CKD.
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Funding for this educational program was provided by unrestricted educational grants from AstraZeneca.
For questions regarding this activity, please contact us at email@example.com.
This is available as accredited online CME for members. Click the button below to enroll:Enroll